

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

POSITIVE PROFIT ALERT

This announcement is made by MicroPort NeuroTech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group and other currently available information for the six months ended 30 June 2024 (the “**Reporting Period**”), the Group is expected to record a net profit of approximately RMB130 million to RMB150 million, representing an increase of approximately 124% to 158% as compared to that of the six months ended 30 June 2023 (the “**Prior-year Period**”).

Based on currently available information, the Board considers that the aforementioned expected increase in the profit of the Group is principally attributable to the following reasons:

- (1) Benefited from the increment in hospital coverage and market share, as well as the rapid development of our oversea business, it is expected that the Group’s revenue for the Reporting Period will increase approximately 34% to 37% as compared to the Prior-year Period;
- (2) Through the implementation of various supply chain improvement projects and cost optimization measures, the Group’s operation efficiency has been advanced and its profitability has been significantly improved.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the unaudited interim results of the Group for the six months ended 30 June 2024 (the “**2024 Interim Results**”). The information contained in this announcement is only a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company. Shareholders and potential investors of the Company are advised to read the Company’s 2024 Interim Results carefully, which is expected to be published by the end of August 2024.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort NeuroTech Limited
Dr. Chang Zhaohua
Chairman

Hong Kong, 23 July 2024

As at the date of this announcement, Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce are the executive directors; Dr. Chang Zhaohua, Mr. Sun Qingwei, Mr. Wang Lin and Ms. Wu Xia are the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao, and Mr. Fan Xin are the independent non-executive directors.